With the rapid scale-up of antiretroviral therapy, there is a dramatic decline in HIV related morbidity and mortality in both developed and developing countries. Several new safe antiretroviral, and newer class of drugs and monitoring assays are developed recently. As a result the treatment guideline for the management of HIV disease continue to change. This review focuses on evolving science on Indian policy--antiretroviral therapy initiation, which drugs to start with, when to change the initial regimen and what to change.
No takes yet. Share an insight, caveat, or question.
Kumarasamy et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: